Oct. 27, 2009 (PR Newswire) --
FRAZER, Pa., Oct. 27 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that Bob Repella has joined as Senior Vice President, U.S Pharmaceutical Operations. In this role, Mr. Repella will have responsibility for managing all aspects of the company's U.S. pharmaceutical and commercial operations, including Sales, Marketing, and Health Care Systems for the company's U.S. product portfolio.
Prior to joining Cephalon, Mr. Repella was Executive Vice President and General Manager of the Biopharma Business Unit for Wyeth Pharmaceuticals. In this position, he was responsible for the global portfolio of products that included Wyeth's biologic, Enbrel (R). During his 16 years at Wyeth, Mr. Repella served in various roles in both Marketing and Sales including Executive Vice President Pharmaceutical Sales, Marketing and Operations; Senior Vice President, Pharmaceutical Sales; Vice President, Global Business Manager Enbrel; Vice President U. S. Marketing Musculoskeletal Products; Vice President U. S. Healthcare Systems Sales, and Assistant Vice President National Accounts.
"We are pleased that Bob has decided to join the Cephalon team to help us with our strategy to both grow our current US business and to build a commercial platform for future products in areas such as biologics," said Robert Roche, Executive Vice President, Worldwide Pharmaceutical Operations. "Bob brings a wealth of diverse experience in the pharmaceutical industry, which will be vital to Cephalon as we continue to expand into new therapeutic areas and address the evolving challenges of this industry."
Earlier in his career, Mr. Repella held positions with Johnson & Johnson's McNeil Pharmaceutical Division, Merck & Co., Inc. and Eli Lilly & Co. Mr. Repella received his Bachelors Degree in Pharmacy from Rutgers University and a Masters in Business Administration from Temple University. He is a member of several boards including BIO, where he also serves on their Executive Committee, and Pennsylvania BIO.
About Cephalon, Inc.
Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of many unique products in four core therapeutic areas: central nervous system, inflammatory diseases, pain and oncology. A member of the Fortune 1000 and the S&P 500 Index, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota.
Cephalon has a growing presence in Europe, the Middle East and Africa.
